150 related articles for article (PubMed ID: 23070047)
21. Prion diseases and emerging prion diseases.
Yokoyama T; Mohri S
Curr Med Chem; 2008; 15(9):912-6. PubMed ID: 18473798
[TBL] [Abstract][Full Text] [Related]
22. Amplification of purified prions in vitro.
Supattapone S; Deleault NR; Rees JR
Methods Mol Biol; 2008; 459():117-30. PubMed ID: 18576152
[TBL] [Abstract][Full Text] [Related]
23. Pathogenic mutations within the hydrophobic domain of the prion protein lead to the formation of protease-sensitive prion species with increased lethality.
Coleman BM; Harrison CF; Guo B; Masters CL; Barnham KJ; Lawson VA; Hill AF
J Virol; 2014 Mar; 88(5):2690-703. PubMed ID: 24352465
[TBL] [Abstract][Full Text] [Related]
24. Chemical induction of misfolded prion protein conformers in cell culture.
Ghaemmaghami S; Ullman J; Ahn M; St Martin S; Prusiner SB
J Biol Chem; 2010 Apr; 285(14):10415-23. PubMed ID: 19955177
[TBL] [Abstract][Full Text] [Related]
25. Packaging of prions into exosomes is associated with a novel pathway of PrP processing.
Vella LJ; Sharples RA; Lawson VA; Masters CL; Cappai R; Hill AF
J Pathol; 2007 Apr; 211(5):582-590. PubMed ID: 17334982
[TBL] [Abstract][Full Text] [Related]
26. Protease-sensitive scrapie prion protein in aggregates of heterogeneous sizes.
Tzaban S; Friedlander G; Schonberger O; Horonchik L; Yedidia Y; Shaked G; Gabizon R; Taraboulos A
Biochemistry; 2002 Oct; 41(42):12868-75. PubMed ID: 12379130
[TBL] [Abstract][Full Text] [Related]
27. Early appearance but lagged accumulation of detergent-insoluble prion protein in the brains of mice inoculated with a mouse-adapted Creutzfeldt-Jakob disease agent.
Nakaoke R; Sakaguchi S; Atarashi R; Nishida N; Arima K; Shigematsu K; Katamine S
Cell Mol Neurobiol; 2000 Dec; 20(6):717-30. PubMed ID: 11100979
[TBL] [Abstract][Full Text] [Related]
28. Residue-specific mobility changes in soluble oligomers of the prion protein define regions involved in aggregation.
Glaves JP; Ladner-Keay CL; Bjorndahl TC; Wishart DS; Sykes BD
Biochim Biophys Acta Proteins Proteom; 2018 Sep; 1866(9):982-988. PubMed ID: 29935976
[TBL] [Abstract][Full Text] [Related]
29. Aβ induces its own prion protein N-terminal fragment (PrPN1)-mediated neutralization in amorphous aggregates.
Béland M; Bédard M; Tremblay G; Lavigne P; Roucou X
Neurobiol Aging; 2014 Jul; 35(7):1537-48. PubMed ID: 24602510
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of non-immunoaffinity methods for isolation of cellular prion protein from bovine brain.
Borges-Alvarez M; Benavente F; Márquez M; Barbosa J; Sanz-Nebot V
Anal Biochem; 2014 Apr; 451():10-7. PubMed ID: 24463017
[TBL] [Abstract][Full Text] [Related]
31. Sialylation of prion protein controls the rate of prion amplification, the cross-species barrier, the ratio of PrPSc glycoform and prion infectivity.
Katorcha E; Makarava N; Savtchenko R; D'Azzo A; Baskakov IV
PLoS Pathog; 2014 Sep; 10(9):e1004366. PubMed ID: 25211026
[TBL] [Abstract][Full Text] [Related]
32. Prion protein oligomer and its neurotoxicity.
Huang P; Lian F; Wen Y; Guo C; Lin D
Acta Biochim Biophys Sin (Shanghai); 2013 Jun; 45(6):442-51. PubMed ID: 23557632
[TBL] [Abstract][Full Text] [Related]
33. Amyloid-beta42 interacts mainly with insoluble prion protein in the Alzheimer brain.
Zou WQ; Xiao X; Yuan J; Puoti G; Fujioka H; Wang X; Richardson S; Zhou X; Zou R; Li S; Zhu X; McGeer PL; McGeehan J; Kneale G; Rincon-Limas DE; Fernandez-Funez P; Lee HG; Smith MA; Petersen RB; Guo JP
J Biol Chem; 2011 Apr; 286(17):15095-105. PubMed ID: 21393248
[TBL] [Abstract][Full Text] [Related]
34. Separation of native prion protein (PrP) glycoforms by copper-binding using immobilized metal affinity chromatography (IMAC).
Müller H; Strom A; Hunsmann G; Stuke AW
Biochem J; 2005 May; 388(Pt 1):371-8. PubMed ID: 15658935
[TBL] [Abstract][Full Text] [Related]
35. Assembly of natural and recombinant prion protein into fibrils.
Leffers KW; Wille H; Stöhr J; Junger E; Prusiner SB; Riesner D
Biol Chem; 2005 Jun; 386(6):569-80. PubMed ID: 16006244
[TBL] [Abstract][Full Text] [Related]
36. Generating Bona Fide Mammalian Prions with Internal Deletions.
Munoz-Montesino C; Sizun C; Moudjou M; Herzog L; Reine F; Chapuis J; Ciric D; Igel-Egalon A; Laude H; Béringue V; Rezaei H; Dron M
J Virol; 2016 Aug; 90(15):6963-6975. PubMed ID: 27226369
[TBL] [Abstract][Full Text] [Related]
37. Lactoferrin induces cell surface retention of prion protein and inhibits prion accumulation.
Iwamaru Y; Shimizu Y; Imamura M; Murayama Y; Endo R; Tagawa Y; Ushiki-Kaku Y; Takenouchi T; Kitani H; Mohri S; Yokoyama T; Okada H
J Neurochem; 2008 Nov; 107(3):636-46. PubMed ID: 18717818
[TBL] [Abstract][Full Text] [Related]
38. Uptake and degradation of protease-sensitive and -resistant forms of abnormal human prion protein aggregates by human astrocytes.
Choi YP; Head MW; Ironside JW; Priola SA
Am J Pathol; 2014 Dec; 184(12):3299-307. PubMed ID: 25280631
[TBL] [Abstract][Full Text] [Related]
39. In vitro conversion and seeded fibrillization of posttranslationally modified prion protein.
Stöhr J; Elfrink K; Weinmann N; Wille H; Willbold D; Birkmann E; Riesner D
Biol Chem; 2011 May; 392(5):415-21. PubMed ID: 21476870
[TBL] [Abstract][Full Text] [Related]
40. Further Characterization of Glycoform-Selective Prions of Variably Protease-Sensitive Prionopathy.
Zhang W; Xiao X; Ding M; Yuan J; Foutz A; Moudjou M; Kitamoto T; Langeveld JPM; Cui L; Zou WQ
Pathogens; 2021 Apr; 10(5):. PubMed ID: 33922765
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
